Ascelia Pharma has carried out a primary issuance of shares of SEK 200 million at a subscription price of SEK 40 per share. The subscription price was determined through an accelerated bookbuilding procedure.
Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Mangoral and Oncoral – in clinical development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm.
Danske Bank and Pareto Securities acted as Joint Bookrunners. Baker McKenzie acted as legal advisor to Danske Bank and Pareto Securities with a Capital Markets team in Stockholm consisting of Joakim Falkner, Johanna Flink and Ian Gulam.